LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial

by Kole Krieger | Apr 2, 2025 | Press Release

Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results...

Congratulations to the Winners of the 9th Annual MTEC Membership Meeting Awards!

by admin | May 29, 2024 | Press Release

Congratulations to the Winners of the 9th Annual MTEC Membership Meeting Awards! Special Recognition Award Presented by Mr. Bill Howell, MTEC President * Winner: Dawn Rosarius, former principal assistant for acquisition MRDC for her contributions and support of MTEC...

Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more

by admin | Jan 19, 2024 | Press Release

Clostridioides difficile, commonly known as C. diff, is a significant health threat in the U.S. Recent estimates suggest that C. diff, a common bacteria, can cause infection in roughly 500,000 patients annually in the U.S., with around 30,000 of these cases resulting...

Lumen Bioscience bags $5.5 million to develop needle-free vaccines

by admin | Nov 30, 2023 | Press Release

Read More

Lumen Bioscience Announces $5.5 Million Funding to Support New Research Program for Mucosal Vaccine Platform Technology

by admin | Nov 29, 2023 | Press Release

– Program aims to provide new technologies for overcoming a key biological limitation in needle-free vaccines Seattle, WA, November 29, 2023 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent...

Lumen Bioscience secures DOD funding for infection treatment

by admin | Oct 22, 2023 | Press Release

Lumen Bioscience co-founder and CEO Brian Finrow said the company is looking for people newly diagnosed with the infection for its trials. Read More